Jim Allison: Breakthrough (2019)

The documentary traces Jim Allison from a small Texas town, where his mother died of lymphoma when he was about ten, to a laboratory career spent on a question few thought worth funding: whether the immune system could be released to attack cancer. Bill Haney lays out the science patiently, from Allison's identification of CTLA-4 as a brake on T cells to his 1996 demonstration in mice that blocking that brake let the immune system reject tumours. The tension is institutional rather than scientific: years of rejection from pharmaceutical companies, an oncology field convinced immunotherapy was a dead end, and an antibody that nearly never reached trials. The film follows its slow route to becoming ipilimumab, approved in 2011 for advanced melanoma, and includes patients who were expected to die and did not. Allison, who plays harmonica in a blues band of immunologists and oncologists called the Checkpoints, is filmed learning he has won the 2018 Nobel Prize, shared with Tasuku Honjo. He lost his brother to prostate cancer in 2005.

Spoilers throughout. Discussing the cancer storyline means discussing how this ends.

Unusually good at conveying how cancer research actually works: slowly, with long stretches of failure, no single eureka moment, and enormous dependence on who is willing to fund a strange idea. It resists the cure-for-cancer framing better than most films of its kind, being clear that checkpoint blockade works dramatically for some patients and not at all for others, and that nobody fully understands why. It shows that immunotherapy is not gentle, with an immune system let off the leash capable of attacking healthy organs. The patient interviews are given time rather than used purely as uplift. And it does not pretend the science rescued the director's subject personally: Allison's own family losses to cancer were not prevented by any of it.

It is an admiring portrait, and the deeply collaborative nature of the discovery gets compressed into one man's persistence; other researchers, including those behind PD-1 blockade, get comparatively little room. The timeline foreshortens years of trial work into a sequence of turning points. Understandably for a film, it foregrounds spectacular responders, which can leave the impression that immunotherapy usually works this well; across most cancers and most patients it does not. Cost, access and the many trials that failed barely feature.

The cancer ipilimumab was first approved for is advanced melanoma. The CDC's ABCDE prompt describes what to look for on skin: Asymmetry, where the two halves of a mole look different; a Border that is irregular or jagged; Colour that is uneven; Diameter larger than a pea; and Evolving, meaning any change over recent weeks or months. The CDC also says to see a doctor about a new growth, a sore that will not heal, or a change in an existing mole. Melanoma can appear on skin that rarely sees the sun, including the soles, palms and under the nails, and on darker skin those sites are proportionally more common, which is a frequent cause of late diagnosis. There is no routine screening programme for average-risk adults. The US Preventive Services Task Force concluded in 2023 that the evidence is insufficient to judge whether whole-body skin examination by a clinician does more good than harm, an I statement, which means unproven rather than proven useless. People with many atypical moles, heavy sun damage, or a personal or family history of melanoma may be offered regular dermatology surveillance, but that is a specialist decision. For everyone else, early detection rests on noticing a change and getting it looked at.

A film is not a diagnosis, and a dramatised illness is not a guide to your own. What a story like this is genuinely good for is lowering the barrier to a conversation you might otherwise put off.

If something in your body has changed and stayed changed for a few weeks, that is worth raising with a doctor — not because it is likely to be cancer, but because most of the time it will not be, and finding that out is the point. Where screening exists for a cancer, it is the one thing you can do before anything is wrong at all. See screening and possible warning signs.

Cancer Explained is free and ad-free. Nothing is sold on this page and no sponsor sits behind it.

If this helped you understand something, or moved you to ask a question you had been avoiding, you can help keep clear cancer information free for whoever needs it next. Support our work.

Jim Allison: Breakthrough is worth watching as a film. It is not a guide to the disease it portrays. The gap between the two is what this page is for — and the thing worth carrying away is that a change which persists is worth a conversation, whatever a story led you to expect.

This page describes a work of film or television for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email [email protected].